

1 **Title:**

2 A survey and antibody test following the surge of SARS-CoV-2 Omicron infection in
3 China.

4

5 **Authors:**

6 Yichuan Yao^{1,2#}, Yunru Yang^{1,2#}, Qiqin Wu^{1,2}, Mengyao Liu^{1,2}, Wei Bao³, Qiutong
7 Wang⁴, Meijun Cheng⁵, Yunuo Chen^{1,2}, Yuan Cai¹, Mei Zhang^{1,2,5}, Jingxue Yao^{1,2},
8 Hongliang He¹, Changjiang Jin⁴, Tian Xue^{1,2,5,6,7*}, Changcheng Zheng^{1*}, Tengchuan
9 Jin^{1,2*}, Dali Tong^{1*}

10

11 **Author Affiliations:**

12 ¹Department of Ophthalmology, The First Affiliated Hospital of USTC, School of Life
13 Sciences, Division of Life Sciences and Medicine, University of Science and
14 Technology of China, Hefei 230026, China.

15 ²School of Life Sciences, Division of Life Sciences and Medicine, University of
16 Science and Technology of China, Hefei 230026, China.

17 ³Institute of Public Health Sciences, Division of Life Sciences and Medicine,
18 University of Science and Technology of China, Hefei 230026, China

19 ⁴The hospital of USTC, University of Science and Technology of China, Hefei 230026,
20 China.

21 ⁵Hefei National Research Center for Physical Sciences at the Microscale,
22 Neurodegenerative Disorder Research Center, CAS Key Laboratory of Brain Function

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 and Disease, CAS Key Laboratory of Innate Immunity and Chronic Disease,
2 Biomedical Sciences and Health Laboratory of Anhui Province, University of Science
3 and Technology of China, Hefei 230026, China.

4 ⁶ Chinese Academy of Sciences Center for Excellence in Brain Science and Intelligence
5 Technology, Chinese Academy of Sciences, Shanghai 200031, China.

6 ⁷Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing
7 100101, China.

8 **#These authors contributed equally**

9 ***Corresponding authors:**

10 **E-mail:**

11 Dali Tong, tdl@ustc.edu.cn

12 Tengchuan Jin, jint@ustc.edu.cn

13 Changcheng Zheng: zhengchch1123@ustc.edu.cn

14 Tian Xue: xuetian@ustc.edu.cn

15 **Address:** Room 718, School of Life Science, West Campus University of Science and
16 Technology of China, No.443 Huangshan Road, Hefei, Anhui, China. 230022.

17 **Telephone:** +86-0551-63600971

1 **Abstract:**

2 The surge of SARS-CoV-2 Omicron infection in most Chinese residents at the end of
3 2022 provided a unique opportunity to understand how the immune system responds to
4 the Omicron infection in a population with limited contact to prior SARS-CoV-2
5 variants. Moreover, whether the prototype SARS-CoV-2 booster vaccination could help
6 induce the antibody against Omicron variants? Here, we tested the level of IgG, IgA,
7 and IgM specific to the prototype SARS-CoV-2 spike RBD (Receptor Binding Domain)
8 from the collected blood samples from 636 individuals. Sequential inoculation of
9 different vaccines showed higher IgG levels after infection. As the antibody level
10 against Omicron BA.5, BF.7, and XBB 1.5 of the individuals has highly positive
11 correlation with the antibody level against prototype SARS-CoV2, the IgG level
12 specific to the prototype SARS-CoV-2 spike RBD could also represent the IgG level
13 against Omicron variants. Furthermore, the 4th booster vaccination could induce a
14 comparable antibody level against prototype, Omicron BA.5, BF.7, and XBB 1.5
15 variants in the patients with 2 or 3-dose vaccination and protect people from being
16 infected. In conclusion, these data suggest that the prototype SARS-CoV-2 booster
17 vaccination helps induce a high level of antibody against prototype, BA.5, BF.7, and
18 XBB 1.5 variants after Omicron infection.

19

1 Coronavirus disease 2019 (COVID-19), caused by a severe acute respiratory syndrome
2 coronavirus 2 (SARS-CoV-2) infection, continues to spread rapidly across the globe
3 and threaten global public health. Since the spread of SARS-CoV-2, it has developed
4 into a lot of variants, such as Alpha, Beta, Delta, Omicron, etc. Currently, the Omicron
5 variant has become the major circulating virus strain, including the Omicron offshoot
6 BA.5, BF.7, XBB and so on. More than 30 mutations in the spike (S) protein and 15
7 mutations in the RBD of the S protein were found in the Omicron variant, which
8 induced the escape neutralization activity of the Omicron variant by most of the
9 identified anti-SARS-CoV-2 neutralization antibodies^{1,2}.

10 Many types of vaccines have been developed to control the infection and spread of
11 SARS-CoV-2, including vaccines based on messenger RNA (mRNA)³, viral vectors^{4,5},
12 recombinant proteins⁶, and inactivated SARS-CoV-2⁷. Immunization with these
13 vaccines showed a reduction in infection rates and post-infection mortality. A booster
14 dose of inactivated SARS-CoV-2 vaccine led to a significant increase in a neutralizing
15 immune response against prototype SARS-CoV-2 and the Omicron variant with
16 incomplete escape⁸. On the other hand, repeated vaccination with inactivated virus
17 vaccine may recall a strong immune response to target the prototype strain because of
18 the immune imprint, while it also inhibits immune responses to new Omicron variants
19 even with the Omicron BA.5 vaccine boost^{1,9}. These reports suggest that current herd
20 immunity may not efficiently prevent the infection of the highly mutagenic Omicron
21 variants.

22 From mid-December of 2022 to early January of 2023, the vast majority of Chinese

1 residents have experienced a surge of SARS-CoV-2 Omicron infection. According to
2 data released by the Chinese Center for Disease Control and Prevention, the SARS-
3 CoV-2 that caused the spread of this current epidemic is mainly Omicron BA.5 and
4 BF.7 variant. Therefore, we conducted a survey 750 people for SARS-CoV-2 infection
5 and collected blood samples from 636 people in Hefei, Anhui Province, China. The
6 demographic and epidemiological characteristics of the 636 people were summarized
7 in Table 1. With regard to the people surveyed, the median age was 32 years
8 (interquartile range: 27 and 49 years; range:2 to 69 years). 22 people were younger than
9 15 years and 57 people were older than 60 years. 308 of them are women. Among the
10 636 people, 441 people were infected as confirmed by antigen or nucleic acid testing,
11 142 people were negative by both testings, with the other 53 people have not been tested
12 by the time of blood collection. The ratio of being tested positive was similar between
13 men and women. The percentage of infected patients increased with age (Spearman
14 Correlation Analysis, $r = 1$, $P = 0.0167$). 611 people (96.07%) are fully vaccinated: 2-
15 dose inactivated SARS-CoV2 vaccine (10.53%); 3-dose recombinant protein vaccines
16 (4.09%); 2-dose inactivated SARS-CoV2 vaccine with 1-dose inactivated SARS-CoV2
17 vaccine booster (57.55%); 2-dose inactivated SARS-CoV2 vaccine with 1-dose
18 recombinant protein vaccine booster (12.42%); 2-dose inactivated SARS-CoV2
19 vaccine with 1-dose AdVs vaccine booster (1.26%); 2-dose mRNA vaccines (0.63%);
20 3-dose mRNA vaccines (0.16%); 4-dose vaccines (8.49%). 19 people (2.99%) were
21 unvaccinated; 4 people (0.63%) were vaccinated with 1-dose inactivated SARS-CoV2
22 vaccine and 2 (0.32%) were vaccinated with 1-dose recombinant protein SARS-CoV2

1 vaccine. Of the 611 fully vaccinated people, 5 people (0.86%) received the latest
2 vaccine less than 7 days; 11 people (1.80%) received the latest vaccine between 7 to 13
3 days; 49 people (8.02%) received the latest vaccine between 14 to 30 days; 6 people
4 (0.98%) received the latest vaccine between 1 to 6 months; and the others (540, 88.38%)
5 received the latest vaccine more than 6 months. The infected percentage was 39.13%
6 in the group that received the last dose vaccine less than 30 days, which is lower than
7 the infected percentage (75.82%) of the group that received the last dose vaccine more
8 than 1 month ago. The result suggested that a boost dose vaccine received in might
9 protect the people from SARS-CoV-2 infection.

10 The clinical characteristics of the 441 individuals who tested positive for antigen or
11 nucleic acid are summarized in Table 2. Only 4 patients (0.91%) reported no special
12 symptom, and the most common symptoms were fever (86.62%), cough (84.6%),
13 weakness (67.35%), sputum production (65.99%), headache (50.79%), myalgia
14 (50.79%), sore throat (49.43%), runny nose (35.37%), loss of taste and smell (30.39%)
15 and conjunctivitis (3.17%). The mean duration of symptoms is 5 days (range, 1 to 20
16 days). 24.26% of patients felt mild symptoms while 12.70% experienced severe
17 symptoms. 355 patients (80.50%) needed medication to relieve symptoms. Drugs
18 included Ibuprofen (93.80%), Paracetamol (44.79%), Chinese medicine (44.79%),
19 Antibiotic (2.82%) and Paxlovid (0.56%).

20 Then, we tested the antibody level, including IgG, IgA, and IgM, of prototype SARS-
21 CoV-2 by a set of chemical luminescence kits that can quantitatively and sensitively
22 measure the levels of IgG, IgA, and IgM specific to the prototype SARS-CoV-2 spike

1 RBD^{10,11}. We found that the IgG of infected patients was higher than that of uninfected
2 people (Figure 1 A). Besides, IgA and IgM levels were low in both the infected patients
3 and the uninfected people, which was lower than the cut-off of the positive control
4 (Figure S1 A and B)¹⁰. As a result, we focus on the analysis of IgG levels. There was
5 no significant change in the IgG level of the patients with different ages, sex, or BMI
6 (Body Mass Index, Figure S1 C-E). The IgG level in patients with severe symptoms is
7 higher than the patients with mild symptoms (Figure 1 B). A similar situation is that the
8 IgG level of patients taking medicines is higher than that of patients with non-drug
9 treatment (Figure 1 C), which may be due to the worse symptoms of the patients who
10 taking medicine (Figure S1 F). No significant changes of IgG were found in the groups
11 with different types of medicines (Figure S2 G).

12 Vaccination is one of the most effective ways to control the spread of SARS-CoV-2.
13 Therefore, we analyzed the IgG levels of people who received the last dose vaccine in
14 different days. The IgG level increased with the time passing by in 30 days (One-way
15 ANOVA of uninfected group, IgG: $P = 0.0005$) and the infection would induce higher
16 IgG level (Figure 1 D). In addition, the vaccination strategy caused different IgG after
17 the Omicron infection. Omicron infection failed to induce measurable IgG levels
18 among those unvaccinated and 1-dose inactivated SARS-CoV-2 vaccinated individuals.
19 Among the fully vaccinated groups, the 2-dose inactivated SARS-CoV2 vaccine with
20 1-dose recombinant protein vaccine booster group showed a higher IgG level than the
21 2-dose inactivated SARS-CoV2 vaccine group ($P = 0.053$) and the 3-dose inactivated
22 SARS-CoV2 vaccine group ($P = 0.026$, Figure 1 E).

1 The prototype SARS-CoV-2 booster vaccination shows a high ability to induce the IgG
2 antibody against prototype SARS-CoV2, while how the prototype SARS-CoV-2
3 booster vaccination help protect the Omicron infection remains unknown. To test the
4 antibody level against different variants of SARS-CoV2, we collected the plasma of 41
5 infected patients (11 unvaccinated patients, 7 with 2-dose inactivated SARS-CoV2
6 vaccine, 13 with 3-dose inactivated SARS-CoV2 or recombinant protein vaccine and
7 10 with 4-dose inactivated SARS-CoV2 or recombinant protein vaccine) and 15
8 uninfected people, including 10 people received the latest boost (4th dose) less than 3
9 months and 5 people received the latest boost more than 6 months. We then tested the
10 antibody titer (IgG) in the plasma against the prototype, Omicron BA.5, BF.7, and XBB
11 1.5 variants using ELISA test⁴. Surprisingly, we found that the antibody level against
12 Omicron BA.5, BF.7, and XBB 1.5 of the individuals has a high positive correlation
13 with the antibody level against prototype SARS-CoV2 (Figure 1 F). These data suggests
14 that the antibody level against prototype SARS-CoV2 could represent the antibody
15 level against the Omicron BA.5, BF.7, and XBB 1.5 of both infected and uninfected
16 people. The results also showed that the infection of Omicron induced a high level of
17 antibody against prototype, Omicron BA.5, BF.7, and XBB 1.5 variants in fully
18 vaccinated patients, which was consistent to the result of chemical luminescence kits.
19 On the other hand, the antibody against Omicron BA.5, BF.7, and XBB 1.5 variants
20 induced by Omicron infection of unvaccinated group was higher than the uninfected
21 fully vaccinated group but not the antibody against prototype SARS-CoV2 (Figure 1
22 G-J). We also found that the 4th booster vaccination could induce comparable antibody

1 level against prototype, Omicron BA.5, BF.7, and XBB 1.5 variants with the 2 or 3-
2 dose infected patients and induced higher antibody level against prototype, Omicron
3 BA.5, BF.7, and XBB 1.5 variants after infection (Figure 1 K-N).

4 In conclusion, in this study with blood samples collected from 636 people in Hefei,
5 Anhui Province, China in middle of January 2023, around 3 weeks after the quick
6 pandemic infection, we found the last booster vaccine received could prevent the people
7 from being infected with SARS-CoV-2. The IgG level of patients with severe symptoms
8 is higher than the patients with mild symptoms. Moreover, the vaccination strategy
9 resulted in different IgG level after the Omicron infection. The Omicron infection could
10 not induce the IgG level in the unvaccinated and 1-dose inactivated SARS-CoV-2
11 patients. The antibody level against Omicron BA.5, BF.7, and XBB 1.5 of the
12 individuals has a high positive correlation with the antibody level against prototype
13 SARS-CoV2. In addition, the 4th booster vaccination could induce the comparable
14 antibody level against prototype, Omicron BA.5, BF.7, and XBB 1.5 variants with 2 or
15 3-dose infected patients and induce higher antibody level after infection. These data
16 suggest that booster vaccination of prototype vaccines could help patients produce
17 higher IgG antibody against the Omicron variants even though it recalls a strong
18 immune response to target the prototype strain because of the immune imprint.

19

20 **Acknowledgments**

21 We thank all colleagues from the First Affiliated Hospital of USTC and the Hospital of
22 USTC, for their support during the study. We thank all of the people who take part in

1 the project for the survey and the blood collection.

2

3 **Funding**

4 This work was supported by the SARS-CoV2 Research and Control Project 2020 (Jack
5 Ma Foundation), National Natural Science Foundation of China (82000941 to D.T.),
6 Fundamental Research Funds for the Central Universities (WK5290000001 to Y.C.,
7 WK5290000002 to Y.Yao.). The study was also supported by Anhui Postdoctoral
8 Scientific Program (D.T.).

9

10 **Conflicts of interest/Competing interests**

11 The authors declare no competing interests.

12

13 **Ethics approval**

14 All procedures were conducted in accordance with the Principles for the Medical
15 Ethical Committee of the First Affiliated Hospital of USTC (approval number: 2023-
16 ky-001).

17

18 **Authors' contributions**

19 D.T., T.J., C.Z., T.X., C.J., and H.H. conceived the project and designed the experiments.
20 D.T., Y. Yao. and Y. Yang. designed and analyzed the questionnaire, tested antibody titer,
21 and wrote the manuscript. Q.Wu. and M. L. did chemical luminescence kits, W. B.
22 analyzed the questionnaire. Q. Wang Collected the blood from the people. M. C., Y.

1 Chen., Y. Cai., M. Z., J. Y., H. H., and C. J. worked on data collection, analysis, and
2 discussion. All authors edited and proofread the manuscript.

3

4 **Reference:**

- 5 1 Cao, Y. *et al.* Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
6 *Nature* **602**, 657-663, doi:10.1038/s41586-021-04385-3 (2022).
- 7 2 Wang, Q. *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and
8 BA.5. *Nature* **608**, 603-608, doi:10.1038/s41586-022-05053-w (2022).
- 9 3 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J*
10 *Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 11 4 Tong, D. *et al.* Single-dose AAV-based vaccine induces a high level of neutralizing antibodies
12 against SARS-CoV-2 in rhesus macaques. *Protein & Cell* **14**, 69-73,
13 doi:10.1093/procel/pwac020 (2022).
- 14 5 Zhu, F. C. *et al.* Immunogenicity and safety of a recombinant adenovirus type-5-vectored
15 COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind,
16 placebo-controlled, phase 2 trial. *Lancet* **396**, 479-488, doi:10.1016/S0140-6736(20)31605-6
17 (2020).
- 18 6 Yang, J. *et al.* A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective
19 immunity. *Nature* **586**, 572-577, doi:10.1038/s41586-020-2599-8 (2020).
- 20 7 Zhang, Y. *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine
21 in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2
22 clinical trial. *Lancet Infect Dis* **21**, 181-192, doi:10.1016/S1473-3099(20)30843-4 (2021).
- 23 8 Yu, X. *et al.* Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization
24 elicited by booster vaccination. *Cell Discov* **8**, 4, doi:10.1038/s41421-022-00375-5 (2022).
- 25 9 Gao, B. *et al.* Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing
26 antibodies against Omicron variants in breakthrough infection. *Cell Res*, 1-4,
27 doi:10.1038/s41422-023-00781-8 (2023).
- 28 10 Ma, H. *et al.* Serum IgA, IgM, and IgG responses in COVID-19. *Cell Mol Immunol* **17**, 773-
29 775, doi:10.1038/s41423-020-0474-z (2020).
- 30 11 Ma, H. *et al.* Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19
31 patients within 100 days after hospital discharge. *Sci China Life Sci* **64**, 482-485,
32 doi:10.1007/s11427-020-1805-0 (2021).

33

- 1 Table1. Demographics and baseline characteristics of the uninfected people and patients
- 2 infected with SARS-CoV2 Omicron variants.

Characteristics	No. (%) of people ^a
Age groups, years	
0-15	22 (3.46%)
16-30	206 (32.39%)
31-45	203 (31.92%)
46-60	148 (23.27%)
>60	57 (8.96%)
Sex	
Male	328 (51.57%)
Female	308 (48.43%)
Confirmed with SARS-CoV2 infection ^b	
Uninfected	142 (22.33%)
Infected	441 (69.34%)
Not sure	53 (8.33%)
Infection of male	
Uninfected	74 (22.56%)
Infected	224 (68.29%)
Not sure	30 (9.15%)
Infection of female	
Uninfected	68 (22.08%)
Infected	217 (70.45%)
Not sure	23 (7.47%)
Age	
0-15	8 (36.36%)
16-30	137 (66.50%)
31-45	139 (68.47%)
46-60	112 (75.68%)
>60	45 (78.95%)
SARS-CoV-2 vaccination strategy ^c	
Unvaccinated	19 (2.99%)
1-dose IV	6 (0.94%)
2-dose IV	67 (10.53%)
3-dose IV	366 (57.55%)
3-dose RP	26 (4.09%)
2-dose IV & 1-dose RP	79 (12.42%)
2-dose mRNA	4 (0.63%)
3-dose mRNA	1 (0.16%)
2-dose IV & 1-dose Adv	8 (1.26%)
4-dose vaccine	54 (8.49%)

Interval days of latest SARS-CoV-2 vaccination and diagnosis day	
0-6 Days	0/5 (0%)
7-13 Days	0/11 (0%)
14-30 Days	27 (55%)
1-6 Month	6 (100%)
>6 Month	408 (76%)

- 1 a. Data are shown as number (%) or number/total number (%) in the 0-6 days and 7-
- 2 13 days of the interval days of latest SARS-CoV-2 vaccination and diagnosis day.
- 3 b. Infected: antigen or nucleic acid testing positive; uninfected: antigen or nucleic acid
- 4 testing negative; Not sure: no antigen or nucleic acid test.
- 5 c. IV: Inactivated SARS-CoV-2 Virus vaccine; RP: Recombinant Protein vaccine;
- 6 mRNA: mRNA vaccine; Adv: Adv-based vaccine.

1 Table. 2 Clinical features of the 441 patients infected with SARS-CoV2 Omicron
2 variants.

Characteristics	No. (%) of patients ^a
Initial presenting symptoms	
Fever	382 (86.62%)
Cough	373 (84.6%)
Weakness	297 (67.35%)
Sputum production	291 (65.99%)
Headache	224 (50.79%)
Myalgia	224 (50.79%)
Sore throat	218 (49.43%)
Runny nose	156 (35.37%)
Loss of taste and smell	134 (30.39%)
Conjunctivitis	14 (3.17%)
Symptom Score ^b	
0-3	107 (24.26%)
4-7	278 (63.04%)
8-10	56 (12.7%)
Medicine-use	
Medicine	355 (80.50%)
Non-medicine	86 (19.50%)
Medicine type ^c	
Ibuprofen	333 (93.80%)
Paracetamol	159 (44.79%)
Chinese medicine	159 (44.79%)
Antibiotic	10 (2.82%)
Paxlovid	2 (0.56%)

- 3 a. Data are shown as number (%)
4 b. Symptom Score was provided by patients, 0: feel no special symptom. 10: feel
5 severest symptom. No patient with severe or critically ill COVID-19 diagnosed by
6 the hospital was involved in the survey.
7 c. The patients who took this kind of medicine were summarized in the table below,
8 and they may take other kinds of medicine at the same time.

- 1 Figure. 1 The booster vaccination of prototype vaccines could help patients produce
2 higher IgG antibody against the Omicron variants.
- 3 A. The IgG level against prototype SARS-CoV2 of the infected and uninfected people
4 tested by chemical luminescence kits. (n = 108 in the uninfected group; n = 441 in
5 the infected group)
- 6 B. The IgG level of infected patients with different symptom score. (n = 107 in the 0-
7 3 group; n = 278 in the 4-7 group; n = 56 in the 8-10 group)
- 8 C. The IgG level of infected patients who take medicine or not. (n = 355 in the
9 medicine group; n = 86 in the non-medicine group)
- 10 D. The IgG level of infected and uninfected people who received the lasted vaccine in
11 6 days, 7-13 days, 13-30 days and 1-6 months. (n = 5 in the 0-6 uninfected days; n
12 = 11 in the 7-13 days uninfected group; n = 22 in the 14-30 days uninfected group;
13 n = 27 in the 14-30 days infected group; n = 6 in the 1-6 months infected group)
- 14 E. The IgG level of infected patients with different vaccination strategy. (IV:
15 Inactivated SARS-CoV-2 Virus vaccine; RP: Recombinant Protein vaccine; n = 19
16 in the unvaccinated group; n = 6 in the 1-dose IV group; n = 67 in the 2-dose IV
17 group; n = 366 in the 3-dose IV group; n = 26 in the 3-dose RP group; n = 79 in the
18 2-dose IV & 1-dose RP group; n = 5 in the mRNA group.
- 19 F. The Pearson correlation coefficient analysis of antibody titer against prototype
20 SARS-CoV2 and Omicron variants. (n = 56)
- 21 G. Quantitative analysis of RBD antibody titer against prototype SARS-CoV2
22 calculated by ELISA. (n = 30 in the fully vaccinated infected group; n = 11 in the

- 1 unvaccinated infected group; n = 5 in the fully vaccinated uninfected group)
- 2 H. Quantitative analysis of RBD antibody titer against Omicron BA.5 variant
- 3 calculated by ELISA. (n = 30 in the fully vaccinated infected group; n = 11 in the
- 4 unvaccinated infected group; n = 5 in the fully vaccinated uninfected group)
- 5 I. Quantitative analysis of RBD antibody titer against Omicron BF.7 variant
- 6 calculated by ELISA. (n = 30 in the fully vaccinated infected group; n = 11 in the
- 7 unvaccinated infected group; n = 5 in the fully vaccinated uninfected group)
- 8 J. Quantitative analysis of RBD antibody titer against Omicron XBB 1.5 variant
- 9 calculated by ELISA. (n = 30 in the fully vaccinated infected group; n = 11 in the
- 10 unvaccinated infected group; n = 5 in the fully vaccinated uninfected group)
- 11 K. Quantitative analysis of RBD antibody titer against prototype SARS-CoV2
- 12 calculated by ELISA. (n = 11 in the unvaccinated infected group; n = 7 in the 2-
- 13 dose infected group; n = 13 in the 3-dose infected group; n = 10 in the 4-dose
- 14 infected group; n = 10 in the 4-dose uninfected group; n = 5 in the fully vaccinated
- 15 uninfected group)
- 16 L. Quantitative analysis of RBD antibody titer against Omicron BA.5 variant
- 17 calculated by ELISA. (n = 11 in the unvaccinated infected group; n = 7 in the 2-
- 18 dose infected group; n = 13 in the 3-dose infected group; n = 10 in the 4-dose
- 19 infected group; n = 10 in the 4-dose uninfected group; n = 5 in the fully vaccinated
- 20 uninfected group)
- 21 M. Quantitative analysis of RBD antibody titer against Omicron BF.7 variant
- 22 calculated by ELISA. (n = 11 in the unvaccinated infected group; n = 7 in the 2-

1 dose infected group; n = 13 in the 3-dose infected group; n = 10 in the 4-dose
2 infected group; n = 10 in the 4-dose uninfected group; n = 5 in the fully vaccinated
3 uninfected group)

4 N. Quantitative analysis of RBD antibody titer against Omicron XBB 1.5 variant
5 calculated by ELISA. (n = 11 in the unvaccinated infected group; n = 7 in the 2-
6 dose infected group; n = 13 in the 3-dose infected group; n = 10 in the 4-dose
7 infected group; n = 10 in the 4-dose uninfected group; n = 5 in the fully vaccinated
8 uninfected group)

9 Values are Median (Min to Max) or geometric mean \pm geometric standard deviation for
10 antibody titer. Mann-Whitney test, *: P < 0.05; **: P < 0.01; ***: P < 0.001.

